Has Boy George confirmed he stopped taking Mounjaro?

No. As of the most recent public record, Boy George has confirmed using Mounjaro but has not publicly stated that he has discontinued it. Any claims about cessation remain speculative.

How much weight do people typically regain after stopping tirzepatide?

The SURMOUNT-4 trial showed approximately 14% body weight regain within 36 weeks of switching from tirzepatide to placebo. This represented roughly two-thirds of the weight that had been lost during the active treatment period.

Is it safe to take Mounjaro indefinitely?

Long-term safety data beyond 2 years remains limited. Known monitoring requirements include gallbladder health, thyroid surveillance (due to boxed warning), lean mass preservation, and GI tolerability. The FDA has not placed a maximum duration on use.

Can lifestyle changes alone maintain weight loss after stopping a GLP-1 drug?

For some patients, yes, but the evidence suggests most individuals regain a significant portion of lost weight without pharmacological support. Structured exercise, high-protein diets, and behavioral strategies can slow regain but rarely prevent it entirely in those with obesity as a chronic condition.

Boy George, Maintenance, and What Happens If You Stop

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Boy George, Maintenance, and What Happens If You Stop Image: HealthRX.com clinical image

Boy George's Public Disclosure

In public statements shared across social media and press interviews, Boy George confirmed he had been using Mounjaro (tirzepatide) as part of his weight management approach. The Culture Club frontman did not hedge or deflect. He stated openly that the medication played a role in his physical transformation, which was visible across his public appearances throughout 2024 and into 2025.

His willingness to name the specific drug (rather than vaguely referencing "lifestyle changes") made him one of the more transparent celebrity users of GLP-1 medications. This openness matters because it gives the public a real reference point rather than another ambiguous transformation story.

What Boy George has not publicly confirmed is whether he has discontinued Mounjaro or remains on it. No public interview or social post (as of this writing) documents a cessation. The HealthRX.com Medical Team therefore examines both scenarios below: what the clinical evidence says about stopping, and what it says about staying on.

At a glance

Drug: Mounjaro (tirzepatide), a dual GIP/GLP-1 receptor agonist
Status: Publicly confirmed use by Boy George
Discontinuation known?: Not publicly confirmed either way
Key clinical finding: SURMOUNT-4 trial showed ~14% weight regain within 36 weeks of stopping tirzepatide
Maintenance consideration: Continued use maintains weight loss but requires ongoing monitoring of GI tolerability, gallbladder health, and lean mass preservation

What Tirzepatide Does (and Why Stopping Matters)

Tirzepatide activates both GIP and GLP-1 receptors simultaneously. This dual mechanism reduces appetite through central hypothalamic signaling, slows gastric emptying, and improves insulin sensitivity. The FDA approved Mounjaro for type 2 diabetes in 2022 and its weight-management formulation (Zepbound) in 2023.

The drug does not "fix" the underlying biological drivers of weight regain. Obesity involves persistent changes in appetite-regulating hormones (ghrelin, leptin, PYY) that remain altered even after significant weight loss. When the pharmacological suppression of appetite is removed, these signals reassert themselves. This is not a failure of willpower. It is physiology.

The SURMOUNT-4 Evidence on Discontinuation

The most direct clinical data on stopping tirzepatide comes from the SURMOUNT-4 trial, published in JAMA in 2023. In this randomized withdrawal study:

Participants who achieved ~21% body weight loss on tirzepatide over 36 weeks were then randomized to either continue or switch to placebo.
Those who continued lost an additional 5.5% body weight over the next 52 weeks.
Those switched to placebo regained approximately 14% of their body weight in the same period.
Cardiometabolic improvements (waist circumference, blood pressure, lipids) also reversed in the placebo group.

The pattern is consistent with earlier GLP-1 withdrawal data. The STEP 1 extension trial for semaglutide showed participants regained two-thirds of their lost weight within one year of stopping.

The HealthRX.com Medical Team's Discontinuation Risk Framework

The HealthRX.com Medical Team categorizes GLP-1 discontinuation risk across three domains:

1. Metabolic rebound. Weight regain after GLP-1 cessation is not linear. Studies show the steepest regain occurs in weeks 4 through 20 post-discontinuation, then decelerates but does not plateau at the pre-treatment baseline. Most patients stabilize at a point that is still somewhat below their starting weight, but well above their on-treatment nadir.

2. Psychological impact. Rapid weight regain after pharmacological weight loss carries documented effects on mood and self-efficacy. A 2023 systematic review in Obesity Reviews identified increased rates of disordered eating behaviors in the post-discontinuation period, particularly in patients who had experienced dramatic visible changes.

3. Cardiometabolic reversal. The SURMOUNT-4 data showed that improvements in HbA1c, triglycerides, and systolic blood pressure reversed proportionally to weight regain. For patients who initiated GLP-1 therapy partly for metabolic reasons, discontinuation may reintroduce cardiovascular risk factors.

If Boy George Continues: Long-Term Considerations

Should Boy George (or any patient) remain on tirzepatide indefinitely, the clinical literature identifies several monitoring priorities:

Gallbladder events. GLP-1 receptor agonists are associated with increased gallbladder-related adverse events. A meta-analysis in Diabetes, Obesity and Metabolism found a relative risk of 1.27 for cholelithiasis with GLP-1 RAs compared to placebo. Rapid weight loss compounds this risk independently of the drug.

Lean mass preservation. Weight lost on GLP-1 medications includes lean body mass. The STEP 1 body composition substudy found that approximately 39% of total weight lost was lean mass. Resistance training and adequate protein intake (1.2 to 1.6 g/kg/day) are standard clinical recommendations to mitigate this.

GI tolerability over time. Nausea, the most common side effect, typically attenuates after 8 to 12 weeks at a stable dose. Persistent GI symptoms beyond this window may warrant dose adjustment. Pancreatitis remains a labeled risk, though absolute incidence is low (under 0.3% in key trials).

Thyroid monitoring. Tirzepatide carries a boxed warning regarding medullary thyroid carcinoma based on rodent studies. While human risk remains theoretical, the FDA label contraindicates use in patients with personal or family history of MTC or MEN2.

Practical Clinical Guidance on Tapering

No consensus guideline currently exists for "tapering off" GLP-1 medications. The HealthRX.com Medical Team notes that some clinicians employ a step-down approach (reducing from maximum dose to intermediate dose over 4 to 8 weeks before cessation), though this strategy lacks randomized evidence. The rationale is to allow appetite-regulating systems to partially recalibrate before full withdrawal.

What the evidence does support for maintenance without medication:

Structured dietary patterns with high protein and fiber content
Regular physical activity (150+ minutes moderate or 75+ minutes vigorous per week, per CDC physical activity guidelines)
Behavioral accountability systems (regular weigh-ins, food tracking)
Consideration of lower-intensity pharmacotherapy (e.g., metformin, naltrexone-bupropion) as a bridge

Why This Public Case Matters

Boy George's openness about using Mounjaro removes one layer of stigma around pharmacological weight management. His public visibility means that millions of people see the results and ask the same question: what happens next?

The honest clinical answer is that GLP-1 receptor agonists manage obesity the way antihypertensives manage blood pressure. Stopping the medication does not mean the underlying condition has resolved. The Endocrine Society's 2024 clinical practice guideline on obesity pharmacotherapy explicitly frames these medications as long-term or indefinite therapies for most patients.

Whether Boy George stays on Mounjaro, transitions to a lower dose, or stops entirely is his private medical decision. What the public can take from his example is that using these medications is not cheating, and that the question of "what happens when you stop" has a real, evidence-based answer that deserves honest discussion.

Frequently asked questions

›